Crinetics Pharmaceuticals Inc. (CRNX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Crinetics Pharmaceuticals... (CRNX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

35.63

-3.35 (-8.59%)

At close: Jan 14, 2025, 3:59 PM

35.62

-0.03%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	14.25
Market Cap	3.30B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.7
PE Ratio (ttm)	-9.63
Forward PE	n/a
Analyst	Buy

Ask	55.8
Volume	1,598,152
Avg. Volume (20D)	735,678
Open	39.10
Previous Close	38.98
Day's Range	35.56 - 39.53
52-Week Range	35.24 - 62.53
Beta	undefined

About CRNX

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat c...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 18, 2018

Employees 290

Stock Exchange NASDAQ

Ticker Symbol CRNX

Website https://www.crinetics.com

Analyst Forecast

According to 10 analyst ratings, the average rating for CRNX stock is "Buy." The 12-month stock price forecast is $73.5, which is an increase of 106.29% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Crinetics Pharmaceuticals Inc. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $700.00K, reflecting a n/a YoY growth and earnings per share of -0.9, making a 0.00% YoY.

Why Price Moved

2 months ago · Source

+1.26%

Crinetics Pharmaceuticals shares are trading highe... Unlock content with Pro Subscription

5 months ago · Source

-6.11%

Crinetics Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results. Additionally, the company announced its CFO will be departing and Oppenheimer lowered its price target on the stock from $74 to $73.

News

1 week ago · seekingalpha.com

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness

Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, ...

2 months ago · seekingalpha.com

Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder a...